Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.

Slides:

Advertisements

Similar presentations

Circ Cardiovasc Interv

Advertisements

Fan et al. Am J Nephrol 2017;45: (DOI: / )

Comparison between Kaplan-Meier survival estimates of Bristol aortic valve surgery patients and the Monte Carlo-based generated Kaplan-Meier curve using.

Comparison between Kaplan-Meier survival estimates of Bristol aortic valve surgery patients and the Monte Carlo-based generated Kaplan-Meier curve using.

Kaplan-Meier survival curves comparing survival between both time periods according to management strategy. Survival in patients with infective endocarditis.

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort by Raphael Itzykson, Sylvain.

Kaplan–Meier survival curves of overall survival (OS) for EGFR mutant lung adenocarcinoma patients who received epidermal growth factor receptor tyrosine.

Kaplan–Meier survival curves of all-cause mortality in patients with idiopathic pulmonary fibrosis (IPF). Kaplan–Meier survival curves of all-cause mortality.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

(A) Kaplan-Meier renal survival estimates of patients with diabetic nephropathy (DN), non-diabetic renal disease (NDRD) and mixed groups, adjusting for.

Kaplan–Meier estimates of the incidence of first heart failure hospitalization during follow-up according to the statin category among patients with type.

Kaplan-Meier curves for overall survival (OS) probability.

Langsford et al. Am J Nephrol 2017;45: (DOI: / )

Neal A. Chatterjee et al. JCHF 2014;2:

Kaplan-Meier estimate of mortality in 1798 propensity score matched pairs with a propensity score >0.5 for the whole observational period. Kaplan-Meier.

Kaplan-Meier plot of incident CVD according to the treatment group over a 4-year period following intensification of diabetes therapy. Kaplan-Meier plot.

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

Kaplan-Meier plots of hHF: DPP-4i and SU cohort with baseline CVD (panel A); saxagliptin and sitagliptin cohorts with baseline CVD (panel B); DPP-4i and.

Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. Kaplan-Meier survival curves for the development.

Kaplan-Meier curves showing the time in months to the first inappropriate shock from the start of remote monitoring in primary and secondary prevention.

Michael J. Germain, MD, Sara N. Davison, MD, Alvin H. Moss, MD

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

(A) Mortality in patients with heart failure and different estimated glomerular filtration rate (eGFR) strata, crude survival assessed by Kaplan-Meier.

Cumulative incidence of monotherapy failure in matched samples of sulfonylurea (n=717) versus metformin (n=3585), when followed for up to 5.5 years. Cumulative.

Survival and telomere length of G2tert−/− zebrafish in a p53−/− background. Survival and telomere length of G2tert−/− zebrafish in a p53−/− background.

A: Kaplan-Meier curves depicting the cumulative probability of CVE in patients with low (

The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.

Stavros V. Konstantinides et al. JACC 2017;69:

Age-adjusted OR (A) and multivariate-adjusted OR (B) and 95% CI for the presence of retinopathy and albuminuria by quintiles of WBC count in 3,776 patients.

Jeffrey J. Teuteberg et al. JCHF 2015;3:

Pooled risk with 95% CI of ACM (A) and CVD risk (B) for the highest vs

Kaplan-Meier survival estimates for major cardiovascular events.

Kaplan-Meier estimation of diabetes-related survival curves in patients grouped according to increased 24-h proteinuria (A), the presence of preexisting.

Two-year changes in albumin-to-creatinine ratio across microalbuminuria at baseline. Two-year changes in albumin-to-creatinine ratio across microalbuminuria.

Effect of age, sex, race/ethnicity, and obesity on the relation of glycemic measures to Si and AIR. In linear regression models with Si as the dependent.

Kaplan-Meier curves depicting the probability of survival from study enrollment in patients receiving conventional chest physical therapy (CCPT) (solid.

Multivariate-adjusted HRs (95% CI) for deaths from CV disease (CVD), coronary heart disease (CHD), stroke, and all-cause mortality according to fasting.

The Kaplan-Meier curves display the time to event for the primary outcome (A) and total mortality (B) during follow-up from randomization until the end.

Kaplan-Meier curves for the end point all-cause mortality in the total patient population stratified according to complete/incomplete revascularisation.

Comparison of survival in patients with BAV (A) and TAV (B) in the US cohort using Kaplan-Meier curves, stratified by whether or not they had suffered.

Insulin sensitivity (Si-clamp) in obese and non-obese study subjects (A) and cumulative incidence of pre-diabetes/type 2 diabetes in insulin-resistant.

A: Incidences of all-cause mortality, coronary artery events, and cerebrovascular events by quartiles of baPWV during the follow-up period. A: Incidences.

Forest plot and pooled estimates of the effect of NAFLD on the risk of incident diabetes in 16 eligible studies, stratified by length of follow-up (FU)

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.

Kaplan-Meier survival curve for CVD mortality among physically active and inactive type 2 diabetic patients stratified by baseline hs-CRP levels. Kaplan-Meier.

Kaplan-Meier estimate of mortality in the two treatment strategies with significant difference between the two groups (log-rank test

For patients with type 2 diabetes and DN, follow-up time was divided into time spent in the following clinical states: DN, CVD, and ESRD in chronologic.

Survival curves according to the presence of late gadolinium enhancement (LGE) and elevated high-sensitivity C reactive protein (hs-CRP). Survival curves.

Trends in mortality by age-groups and select CVDs among adults with diabetes. Trends in mortality by age-groups and select CVDs among adults with diabetes.

Kaplan-Meier analysis for the cumulative percentage of patients who remained hospitalized according to presence or absence of ARF with or without other.

Kaplan-Meier curves of ventricular arrhythmia–related events (A), death from MI (B), or both end points combined (C). Kaplan-Meier curves of ventricular.

Progression to micro- or macroalbuminuria.

Kaplan-Meier survival curves for canine patients with (n = 3; huTyr Ab+) and without (n = 6; huTyr Ab-) positive humoral responses to the xenogeneic huTyr.

Kaplan-Meir survival plots for CHD mortality (A), CVD mortality (B), and all-cause mortality (C) in men grouped by TG/HDL-C ratio of 3.5. Kaplan-Meir survival.

Adjusted all-cause (A) and CVD (B) mortality HRs (95% CIs) for IFG, IGT, NDM, and KDM compared with NGT according to ethnic group. Adjusted all-cause (A)

Kaplan-Meier plots of the duration of continuous albuterol, time until q4 albuterol, and hospital LOS for each of the 4 treatment groups. Kaplan-Meier.

Plots of average estimated and measured GFR vs

Somatic mutational rates and survival analysis of IBD-CRC.

A: Probability of retinopathy-free survival.

Kaplan-Meier survival analysis of p53 mutation in the overall breast tumor series. Kaplan-Meier survival analysis of p53 mutation in the overall breast.

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML by Claire M. Lucas, Laura J. Scott, Natasha Carmell,

Mortality rate according to our integrated index that combines DH and exercise capacity. Mortality rate according to our integrated index that combines.

Kaplan-Meier survival (renal event-free) curves during follow-up by tertiles of plasma copeptin. Kaplan-Meier survival (renal event-free) curves during.

Complex association between Hb level and GFR, sex, and AER

Risk of mortality in patients with diabetes and ESRD

WM volume did not show the expected increase in volume with age in children with type 1 diabetes (●), in contrast with HC subjects (▲) who showed the (expected)

Expression of TGFβ ligands in GBM

(A). (A). Kaplan-Meier plot of event-free survival in 27 LMNA mutation carriers and 78 DCM control patients. Death, heart transplantation, resuscitation.

Kaplan-Meier curves showing the probability of symptom-free survival according to the rate of heart rate rise during exercise testing in (A) for the whole.

Presentation transcript:

Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation. Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation. The overall statistical significance was estimated by the log-rank test (P < 0.0001 for all). Giovanni Targher et al. Dia Care 2012;35:2347-2353 ©2012 by American Diabetes Association